Regardless of whether the patient has co-occurring VHL and BAP1 mutations or co-occurring VHL and PBRM1 mutations, T cell activation genes form coordinated co-expression in the tumor (Fig. 3). This evidence concerns the gene BAP1 and neoplasm.